As scientists successfully decode and isolate human DNA in the race for new drugs, the ability to protect and profit from what they find has yet to be mapped. A federal appeals court is poised to tie that loose end when it hears arguments on whether it should be legal to obtain U.S. patents on genetic material and on methods of using that DNA for medical diagnoses and treatments. Madeleine Ball, HMS research fellow in genetics, is quoted.
